Summaries by Inventor Sharma, Vijay
Piwnica-Worms, David ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-010438
— Technology Description Researchers at Washington University in St. Louis have developed a novel positron emission tomography (PET) radiopharmaceutical for myocardial perfusion imaging. Myocardial perfusion scintigraphy is widely employed in the evaluation of patients with heart disease. Several ag…
PET Radiotracers Capable of Crossing the Blood Brain Barrier and Detecting Reactive Oxygen SpeciesSatham, Lakshminarayana ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-020300
— T-020300 PET Radiotracers Capable of Crossing the Blood Brain Barrier and Detecting Reactive Oxygen Species Technology Description Reactive Oxygen Species (ROS) is known to contribute to the pathogenesis of neuropathological conditions such as Alzheimer’s disease and cancer. However, there…
Tissue-penetrating PET radiotracer for non-invasive detection of ROS and inflammationSharma, Vijay ; Sivapackiam, Jothilingam
T-019479
— T-019479 Tissue-penetrating PET radiotracer for non-invasive detection of ROS and inflammation. Technology Description 18F-fluorodeoxyglucose (18F-FDG) has long been used for the diagnosis of neoplasms, and recently Alzheimer’s disease. However, 18F-FDG signals are often not correlated with…
PET tracers for detection of early stage Alzheimer’s diseaseGuruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-013525
— Technology Description Researchers at Washington University in St. Louis have developed PET radiotracers to image amyloid beta (A-beta) at early stages of Alzheimer’s Disease (AD). For AD treatment to be effective, it may have to be administered during the preclinical stage. As such, there i…
Design and Development of Organomedicinals for Imaging and Treatment of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (FTD)Guruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-016665
— Background Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…
Nanomaterials for Imaging and Treatment of AmyloidosisBieschke, Jan ; Guruswami, Sundaram ; Liu, Yongjian ; Sharma, Vijay
T-017876
— Background 8 million people per year are diagnosed with light-chain (AL) amyloidosis, a progressive disease than can quickly affect the kidney, heart, and nervous system if left untreated. The current method of diagnosis involves histological confirmation via biopsies of bone marrow, fat, and organ…
